Dunno about that, great looking daily charts, very strong. Easy to forget that Ariad has an FDA approved drug for treating 2 deadly diseases, 2nd line treatment with some possible risks weighed against the certainty of death. I'll say again. Had Ariad chosen not to pursue expanded indications, the EPIC trial never would have happened, the FDA holds never would have happened, Ariad's decision to discontinue the trial never wopuld happened and we would not be witness to this tumble. Without the hope of expanded indications and expanded sales to follow, ARIA would never seen $25. But it never would have been down here either. So teh question is, where would ARIA be right now without the EPIC trial. $4? I doubt it, and so do you. I think it would have been in the low teens right now. The smoke is clearing and people are beginning to see that logic. The shock of the discontinued trial has clouded the ability of most to see the intrinsic value here as a 2nd line treatment for 2 forms of resistant leukemia, the indication it was developed and approved for in the first place. It won't reach low teens anytime soon, but $4 is illogical. I suspect $8-9 by year's end.